Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials
Indianapolis, August 17, 2010 (ots/PRNewswire) - Eli Lilly and Company will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary...
- 17.08.2010, 14:01:36
- /
- OTE0006